SNS-062 is an experimental BTK inhibitor like ibrutinib or the experimental acalabrutinib but it binds differently than ibrutinib and acalabrutinib.
In vitro data suggests resistance should be less likely due to this difference in binding. It suggest that its efficacy should not be compromised by the most common known cause of BTK resistance, namely a mutation in the C481 binding site where the two other drugs bind.
This study will help sort this and any other issues in relapsed patients who have already failed a BTK inhibitor.
It is only through trials like this does the science move forward. The treatment options for patients who failed ibrutinib is getting better, but is still a challenge.